1型糖尿病成年人对DASH的治疗满意度:一个非盲目的1:1随机对照试验
Yee Wen Kong1,2, Cheng Yi Yuan1,2, Katerina Kiburg1,2
1Diabetes Technology Research Group, The University of Melbourne, Melbourne, Victoria 3065, Australia.
The Journal of clinical endocrinology and metabolism
|February 19, 2024
概括
与常规护理相比,Omnipod DASH系统显著提高了1型糖尿病成年人的治疗满意度. 这种益处持续了24周,也改善了血糖控制.
科学领域:
- 内分泌学 在内分泌学.
- 医疗器械 医疗器械
- 糖尿病 技术 技术
背景情况:
- 奥姆尼波德DASH胰岛素管理系统为传统胰岛素疗法 (IPT) 提供了一个无管替代方案,解决身体不便.
- 1型糖尿病的管理通常涉及多次每日注射 (MDIs) 或管式IPT.
研究的目的:
- 在使用自监测血糖 (SMBG) 的1型糖尿病成年人中,比较Omnipod DASH系统和常规护理 (MDIs或管式IPT) 之间的治疗满意度.
主要方法:
- 一项为期12周的非盲目随机试验将1型糖尿病 (在MDI或IPT) 的成年人分配给Omnipod DASH系统或通常护理.
- 主要结局是治疗满意度,通过12周糖尿病技术问卷"当前" (ΔDTQ-current) 得分的变化来衡量.
- 二次结局包括参与者报告的24周生命质量,治疗负担和血糖控制的结果 (PROs).
主要成果:
- 与12周的常规护理组相比,Omnipod DASH组在治疗满意度上显示出显著更大的改善 (ΔDTQ-current: 16.4 vs 0.0; P < .001).
- 在其他PRO和糖化血红蛋白A1c (HbA1c) 水平上也观察到显著的改善.
- 虽然时间范围在12周没有差异,但在Omnipod DASH组 (5.6%;P = .016) 中,时间范围在24周内显著改善.
结论:
- 欧姆尼波德DASH系统提高了SMBG使用的1型糖尿病成年人治疗满意度,在24周内持续获得好处.
- 该系统没有影响睡眠质量,也没有增加对低血糖的恐惧.
- 使用Omnipod DASH系统观察到血糖控制的改善,包括HbA1c和范围内的时间.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
172
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
172
Diabetes: Management and Pharmacotherapy
283
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
283
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Symptoms, Diagnosis, and Complications
539
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
539
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K


